COPD pp 65-74 | Cite as

Diagnosis and Assessment of COPD

  • Yong Bum ParkEmail author


A clinical diagnosis of COPD should be considered in patients over the age of 40 who present with dyspnea, chronic cough or sputum production, and a history exposure to risk factors for the disease. Spirometry is fundamental to making a diagnosis of COPD, and the presence of a post-bronchodilator FEV1/FVC < 0.70 confirms the presence of persistent airflow limitation. COPD assessment is to determine the severity of disease, including the severity of airflow limitation, the impact on the patient’s health status, and the future risk. COPD assessment is important for therapy and prognosis. COPD often coexists with comorbidities that may have significant impact on mortality and prognosis. At the initial assessment and follow-up visits should include a discussion of symptoms, particularly any new or worsening symptoms and physical examination.


  1. 1.
    Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Morkve O. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J. 2002;20(5):1117–22.CrossRefGoogle Scholar
  2. 2.
    Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax. 2008;63(12):1046–51.CrossRefGoogle Scholar
  3. 3.
    Jing JY, Huang TC, Cui W, Xu F, Shen HH. Should FEV1/FEV6 replace FEV1/FVC ratio to detect airway obstruction? A metaanalysis. Chest. 2009;135(4):991–8.CrossRefGoogle Scholar
  4. 4.
    Yoo KH, Kim YS, Sheen SS, Park JH, Hwang YI, Kim SH, Yoon HI, Lim SC, Park JY, Park SJ, Seo KH, Kim KU, Oh YM, Lee NY, Kim JS, Oh KW, Kim YT, Park IW, Lee SD, Kim SK, Kim YK, Han SK. Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and nutrition examination survey, 2008. Respirology. 2011;16(4):659–65.CrossRefGoogle Scholar
  5. 5.
    Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and nutrition examination survey, 1988-1994. Arch Intern Med. 2000;160(11):1683–9.CrossRefGoogle Scholar
  6. 6.
    Walker PP, Mitchell P, Diamantea F, Warburton CJ, Davies L. Effect of primary-care spirometry on the diagnosis and management of COPD. Eur Respir J. 2006;28(5):945–52.CrossRefGoogle Scholar
  7. 7.
    Stockley RA, O’Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000;117(6):1638–45.CrossRefGoogle Scholar
  8. 8.
    Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and Prevent of chronic obstructive pulmonary disease, updated 2015.
  9. 9.
    Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581–6.CrossRefGoogle Scholar
  10. 10.
    Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002;121(5):1434–40.CrossRefGoogle Scholar
  11. 11.
    Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117(5 Suppl 2):398S–401S.CrossRefGoogle Scholar
  12. 12.
    Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl. 2003;41:46s–53s.CrossRefGoogle Scholar
  13. 13.
    Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 2007;29(6):1224–38.CrossRefGoogle Scholar
  14. 14.
    Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196–204.CrossRefGoogle Scholar
  15. 15.
    Leidy NK, Wilcox TK, Jones PW, et al. Development of the EXAcerbations of chronic obstructive pulmonary disease tool (EXACT): a patient-reported outcome (PRO) measure. Value Health. 2010;13:965–75.CrossRefGoogle Scholar
  16. 16.
    Jones PW, Chen WH, Wilcox TK, et al. Characterizing and quantifying the symptomatic features of COPD exacerbations. Chest. 2011;139:1388–94.CrossRefGoogle Scholar
  17. 17.
    Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and Prevent of chronic obstructive pulmonary disease, revised 2011.
  18. 18.
    Korean Academy of Tuberculosis and Respiratory Diseases. COPD guideline revised 2014.
  19. 19.
    Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, Riesco JA, Trigueros JA, Piñera P, Simón A, Rodríguez-Hermosa JL, Marco E, López D, Coll R, Coll-Fernández R, Lobo MÁ, Díez J, Soriano JB, Ancochea J. Spanish guideline for COPD (GesEPOC). Arch Bronconeumol. 2014;50(Suppl 1):1–16. doi: 10.1016/S0300-2896(14)70070-5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Division of Pulmonary, Allergy and Critical Care MedicineHallym University Medical CenterSeoulSouth Korea
  2. 2.Department of Internal MedicineHallym University Kangdong Sacred Heart HospitalSeoulSouth Korea
  3. 3.Lung Research Institute of Hallym University College of MedicineSeoulSouth Korea

Personalised recommendations